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Walleye dermal sarcoma virus (WDSV) is a complex retrovirus associated with seasonal dermal sarcomas. Developing tumors have low
levels of accessory gene transcripts, A1 and B, and regressing tumors have high levels of full-length and spliced transcripts. Transcript A1
encodes a retroviral cyclin (rv-cyclin) with limited homology to host cyclins. The rv-cyclin is physically linked to components of the
transcriptional co-activator complex,Mediator, and regulates transcription. In walleye fibroblasts, it inhibits theWDSVpromoter independently
of cis-acting DNA sequences. The rv-cyclin activates transcription from GAL4 promoters when fused to the GAL4 DNA binding domain. A 30
a.a. activation domain in the carboxy region can be inactivated by single point mutations, and these mutations diminish the ability of the rv-
cyclin to inhibit the WDSV promoter. When fused to glutathione S-transferase, the rv-cyclin, its carboxy region, and the activation domain pull
down components of transcription complexes from nuclear extracts, and pulldown is lost by mutation of the activation domain.
D 2005 Elsevier Inc. All rights reserved.Keywords: WDSV; rv-cyclin; cdk8; Cyclin C; Sur2; TBP; VP16; MediatorIntroduction
Walleye dermal sarcoma virus (WDSV), a member of
the Epsilonretroviruses in the family Retroviridae, is a
complex retrovirus etiologically associated with dermal
sarcomas in walleye fish (Stizostedion vitreum) (Martineau
et al., 1991, 1992; Walker, 1969; Yamamoto et al., 1976,
1985). The seasonal appearance of this disease is
characterized by the expression of low levels (1–100042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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Pittsburgh, PA 15260, USA.copies/cell) of spliced accessory gene transcripts, A1 and
B, during the period of tumor development in the fall and
winter and high levels (500–1000 copies/cell) of full-
length and spliced transcripts during tumor regression in
the spring (Quackenbush et al., 1997; Rovnak et al.,
2001).
Transcript A1 encodes a retroviral cyclin (rv-cyclin, Orf
A1 protein), with a cyclin box motif but with limited
homology to host cyclins (LaPierre et al., 1998). Homo-
logues of the rv-cyclin of WDSV are encoded by walleye
epidermal hyperplasia virus types 1 and 2 (WEHV-1 and
WEHV-2), but these smaller rv-cyclins do not contain the
carboxy-terminal region of the WDSV cyclin (Bowser et al.,
1988, 1996; LaPierre et al., 1998, 1999; Quackenbush et al.,
1997). The rv-cyclin from WDSV, but not from WEHV-1 or
WEHV-2, was able to induce cell-cycle progression in G1-
cyclin deficient yeast (LaPierre et al., 1998). The WDSV rv-
cyclin was also associated with the induction of hyperplastic
skin lesions in transgenic mice when expressed from a
keratin promoter (Lairmore et al., 2000).05) 240 – 251
J. Rovnak et al. / Virology 342 (2005) 240–251 241When expressed in mammalian or piscine cell culture, the
WDSV rv-cyclin was localized in the nucleus and concen-
trated in interchromatin granule clusters (IGCs) (Rovnak et
al., 2001), nuclear domains enriched in proteins necessary
for mRNA transcription and processing. The first 112 amino
acids were necessary for localization in IGCs. The rv-cyclin
was found, by co-immunoprecipitation (coIP), to be physi-
cally associated with cyclin dependent kinase 8 and cyclin C
(Rovnak and Quackenbush, 2002), components of a large,
multi-protein complex generally known as Mediator. Medi-
ator, first identified in yeast, regulates activation and
repression of transcription (reviewed in Blazek et al.,
2005; Conaway et al., 2005; Roeder, 2005). Similar
complexes, such as TRAP/SMCC, PC2, CRSP, ARC-L,
and DRIP, have been identified in metazoan organisms.
These complexes vary in overall subunit composition and
this variation corresponds with Mediator function.
In walleye cell culture systems, where WDSV promoter
activity is low, exogenous rv-cyclin further inhibited tran-
scription from the WDSV promoter in a luciferase reporter
system (Rovnak and Quackenbush, 2002; Zhang and
Martineau, 1999), and this inhibition was independent of
sequences in the R and U5 regions of the LTR. However,
other viral promoters, such as that of SV40, were found to
be activated by exogenous rv-cyclin in the same fish cells
(Rovnak and Quackenbush, 2002). In select mammalian
cells, rv-cyclin activated the WDSV promoter and inhibited
SV40, demonstrating its ability to either inhibit or activate
transcription in a manner dependent on both the promoter
and the cell type (Rovnak and Quackenbush, 2002). The
regulation of transcription and the physical association of
the rv-cyclin with Mediator components, cdk8 and cyclin C,
were dependent upon intact amino- and carboxy-terminal
regions of the protein (Rovnak and Quackenbush, 2002).
The ability of the rv-cyclin to activate transcription was
tested directly in yeast and cell culture from metazoan
organisms with GAL4 DNA binding domain (DBD) fusion
proteins. This approach allows the isolation of activation
domains (ADs) that can replace the GAL4 AD function in
transcription initiation from a GAL4 promoter. Herein we
define and characterize an rv-cyclin activation domain (AD)
and identify interacting transcription co-activators. The
results support a model in which the rv-cyclin of WDSV
differentially regulates transcription by the modulation of
protein–protein interactions to control the composition of
the transcriptional complex.Fig. 1. (A) Consecutive 50 bp deletions from the 5V end of the WDSV U3
region (d1–d7) were tested for the ability to drive luciferase expression in
walleye fibroblast W12 cells without (white bars) or with expressed rv-
cyclin (black bars). (B and C) Assays, as in panel A, of the WDSV U3
region with specific mutations in either the enhancer (B) or core promoter
region (C). Functional mutations within the indicated sites were defined
previously by DNA footprinting, electrophoretic mobility shift assays, and
luciferase assays (Hronek et al., 2004).Results
rv-cyclin inhibition of the WDSV promoter functions
independently of specific sequence recognition
The inhibitory effects of the rv-cyclin on the basal
activity of the WDSV promoter in piscine cells were
previously determined to be independent of sequence withinthe R or U5 regions of the LTR (Rovnak and Quackenbush,
2002). The effects of the rv-cyclin on the WDSV promoter
were tested with a variety of U3 region mutations (Fig. 1).
Table 1
Activation of transcription in yeast
Construct Colony-lift
filter assay
h-galactosidase units
(mean T SD)
pAS2-1  0.03 T 0.01
pAS2-1 A1– 297 + 0.67 T 0.28
pAS2-1 A95 – 297  0.02 T 0.01
pAS2-1 A112 – 297  0.03 T 0.01
pAS2-1 A1– 219  0.02 T 0.01
pAS2-1 A112 – 219  0.03 T 0.01
pAS2-1 A1– 112  0.03 T 0.00
pAS2-1 A219 – 297 + 3.33 T 1.12
pTD1-1/pVA3-1a + 72.68 T 37.26
a Positive control DBD and AD vectors.
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region in the pGL3WDSVU3 construct (Hronek et al.,
2004) were assessed individually for inhibition of promoter
activity by the rv-cyclin (Fig. 1A). HA-tagged rv-cyclin was
expressed from the construct, pKH3OrfA (Rovnak et al.,
2001). Expression from each functional deleted promoter
was subject to greater than 2-fold inhibition when the rv-
cyclin was present. Deletions d6 and d7 did not display
substantial levels of transcription activity with or without rv-
cyclin. These mutations delineated the core promoter of
WDSV (Hronek et al., 2004).
In addition to the deletion mutants, point mutations
within 13, known cis-acting sites were assayed in the
presence of the rv-cyclin. The selected sequences were
previously identified by DNA footprinting and electro-
phoretic mobility shift assays (Hronek et al., 2004). Seven
of these sites reside in the enhancer region (bp 441 to
104) (Fig. 1B) and six of the sites are found within the
core promoter (bp 103 to 1) (Fig. 1C). Expression of the
rv-cyclin reduced WDSV promoter-driven luciferase
expression from all of the mutated promoters (Figs. 1B
and C). These results suggest that the rv-cyclin does not
bind directly to a specific sequence within the enhancer
region in order to affect inhibition (Fig. 1A), and it does not
interact functionally with the known transcriptional activa-
tors that bind the enhancer or core promoter (Figs. 1B and
C). The rv-cyclin protein sequence does not contain a
predicted DNA-binding domain, and purified recombinant
rv-cyclin does not bind to labeled U3 probe in electro-
phoretic mobility shift assays under conditions established
for this probe with known DNA-binding proteins (Hronek et
al., 2004; data not shown).
The WDSV rv-cyclin activates transcription in yeast when
tethered to a promoter
A yeast two-hybrid screen was employed to identify
cellular proteins that interact with rv-cyclin. In preparation
for a two-hybrid screen, the rv-cyclin was fused to the GAL4
DBD (pAS2-1A1–297) and tested for activation of the lacZ
reporter gene from a GAL4 promoter. This DBD-rv-cyclin
fusion protein activated transcription, as determined by the
appearance of blue colonies in a colony lift assay (Table 1).
Fusion of the rv-cyclin with the GAL4 AD did not yield lacZ
expression in this system. These results suggest that the rv-
cyclin contains an activation domain that can replace the
function of the GAL4 AD and excludes its direct interaction
with DNA in GAL4 promoter sequences.
To delineate the region of the rv-cyclin that contained an
activation domain, several GAL4 DBD rv-cyclin deletion
mutants were constructed. Deletions of a.a. 1–95, 1–112,
or 219–297 from the GAL4 DBD-rv-cyclin fusion protein
each eliminated activation of the lacZ reporter (Table 1;
pAS2-1A95–297, pAS2-1A112 –297, and pAS2-1A1–219).
Deletions of 1–95 and 1–112 were selected, because these
forms are encoded by naturally occurring splice variants ofrv-cyclin transcripts, and the amino terminus controls
nuclear localization (Quackenbush et al., 1997; Rovnak et
al., 2001). The carboxy region is exclusive of the cyclin box
motif and contains a predicted coiled-coil domain between
positions 228 and 257. Deletion of either the amino-terminal
95 a.a. or the carboxy-terminal 78 a.a. (219–297) blocked
cell-specific inhibition of the WDSV promoter (Rovnak and
Quackenbush, 2002). To identify the contributions of the
amino and carboxy domains, they were fused individually to
the GAL4 DBD and results measured in a quantitative assay
of h-galactosidase activity (pAS2-1A1–112 and pAS2-
1A219–297; Table 1). Activation of h-galactosidase expres-
sion was limited to either the full-length construct or the
isolated carboxy region, which had a greater level of
expression. Inclusion of the region between a.a. 95 and
219 with the carboxy region completely blocked its ability
to activate transcription in this system.
The WDSV rv-cyclin activates transcription in HeLa cells
Results indicating an activation domain within the
WDSV rv-cyclin were reproduced in HeLa cells (Fig. 2).
Constructs encoding GAL4 DBD-rv-cyclin fusion proteins
from the pFA-CMV vector were co-transfected with a
luciferase reporter construct, pFR-luc, that contains a
minimal promoter with a TATA box and five GAL4-
consensus binding sequences. Western blots with anti-
DBD were performed to confirm protein expression from
all of the constructs tested (not shown). The GAL4 DBD nls
sequence confers nuclear localization on the expressed
fusion proteins. Consistent with the results in the yeast
system, the full-length rv-cyclin (1–297) activated lucifer-
ase expression, but amino- or carboxy-truncated forms (33–
297, 95–297, 112–297, and 1–219) were unable to activate
luciferase expression when tethered to the GAL4 consensus
sequences (Fig. 2). Although deletion of the first 33, 95, or
112 a.a. eliminated activation, regions 1–95, 1–112, and 1–
219 were not able to activate transcription when fused to the
GAL4 DBD. As observed in yeast experiments, the
carboxy-terminal 78 a.a.-DBD fusion protein (219–297)
was able to activate transcription (Fig. 2), but inclusion of
any of the segments between a.a. 33 and 219 blocked this
Fig. 2. Assay of transcription activation by rv-cyclin and rv-cyclin fragments in HeLa cells. Indicated portions of the rv-cyclin protein were fused to the GAL4
DBD, and their ability to activate luciferase expression from the pFR-luc GAL4 reporter construct measured after 48 h. Boundaries of each segment are
indicated by a.a. position at the top. The outlines of the predicted cyclin box folds, here designated FCyclin box A_ and FCyclin box B_ are indicated. FCC_
represents the putative coiled-coil region. The smallest active region, a.a. 228–283, is indicated.
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a putative phosphorylation target at serine 285, enhanced
activation by both the full-length and carboxy region fusions
to a significant degree (P  0.05) (Fig. 2). A DBD-fusion of
just the predicted coiled-coil region (228–255) was not able
to activate transcription, and tests with fragments over-
lapping this region, 219–255 and 228–283, identified the
region between 228 and 283 as inclusive of an activation
domain. These results confirm a transcription activation
function of the rv-cyclin in metazoan organisms. Amino-
terminal truncations at positions 33, 95, and 112 would
likely disrupt the structure of the first putative cyclin box
fold (the region containing the first five alpha helices
designated ‘‘Cyclin box A’’). Such structural disruption may
disrupt the function of the fusion proteins that include the
region between 33 and 219.
A WDSV AD can be identified by comparison with a known
activation domain
In order to further delimit the rv-cyclin AD, sequences
from positions 225 to 285 were represented by seven, 31-
a.a. increments, that overlap by 26 a.a.. These increments
were aligned individually with a prototypic acidic activa-
tion domain from HHV1 a-TIF (transcription initiation
factor; VP16; a.a. 425–451; Cress and Triezenberg, 1991)
(Fig. 3A). The 240–270 increment was found to align best
with 5 of 7 characteristic hydrophobic side chains. This
31-a.a. region has a predicted isoelectric point of 4.08. Of
particular interest was the alignment of positions 257–260
(LDDV) with positions 439–442 (LDDF) of the VP16AD. The 240–270 region of the rv-cyclin was cloned into
the GAL4 DBD vector, as were constructs with 5
individual point mutations: L257A, D259A, V260A,
V260S, and V260F. The 240–270 region activated tran-
scription in HeLa cells to a degree similar to the full-length
rv-cyclin fusion protein, and four of the five point mutants
eliminated activation by this region (Fig. 3B). Only the
conservative mutation of valine to phenylalanine at residue
260 maintained activation by the DBD-240–270 fusion.
For comparison, Fig. 3D shows the results from a
luciferase assay with DBD fusions of the entire VP16
AD (a.a. 413–490), VP16N (a.a. 413–452; the H1
subdomain), VP16C (a.a. 453–490; the H2 subdomain),
and mutations of these constructs: one in VP16N, F442S,
one in VP16C, F475A, and both mutations in the full
VP16 AD. The activity of the rv-cyclin AD is approx-
imately 1/30 of the VP16 AD and 1/10 that of the VP16N
and VP16C subdomains in HeLa cells.
When performed in a walleye fibroblast cell line, W12,
the isolated rv-cyclin AD (240–270) activated transcription
(Fig. 3C). As in HeLa cells, mutations L257A, D259A,
V260A, and V260S reduced the activation to levels
comparable to the pFA-CMV control vector, and the
conservative V260F mutation maintained activation (Fig.
3C). Interestingly, the full-length rv-cyclin fused to the
GAL4 DBD has little apparent activity in these cells. These
results distinguish the function of the DBD-fusion, full-
length protein in walleye cells from that in HeLa cells by
extending the apparent inhibitory region between a.a. 33 and
219 to include the first 33 amino acids or the entire cyclin
box region. This result suggests that the intact cyclin box of
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walleye fibroblast cells.
The activities of the VP16 AD and its subdomains,
VP16N and VP16C, were also tested in walleye fibro-
blasts (Fig. 3E). All three DBD fusions activate tran-
scription, but VP16C had greater function in these cells
relative to its activity in HeLa cells and when compared to
the full VP16 AD, VP16N, and the rv-cyclin AD:
approximately 2, 3, and 11 times their activation levels,
respectively (Fig. 3E).
The results from these reporter assays demonstrate
comparable function of the isolated rv-cyclin AD in HeLa
and W12 cells. This suggests a common target for
contact by the AD in mammalian and piscine cells as
well as in yeast. The VP16C activation domain functions
distinctively in W12 cells suggesting variations in the
milieu of HeLa and W12 cells that can allow the
regulation of an activation domain or affect the degree
of activation.
Mutations within the AD affect the function of the full-length
rv-cyclin
The wild type rv-cyclin significantly inhibited expres-
sion from the WDSV promoter to 39% of the activity
found in cells that do not express rv-cyclin (set at 100%
activity) (Fig. 4, P < 0.0001). Mutations D259A and
V260A, which had blocked activation by GAL4-DBD
fusion proteins, reduced the inhibitory action of the rv-
cyclin, resulting in 50% of the luciferase activity (P <
0.03) from the WDSV promoter alone. The L257A and
V260S mutations significantly reduced (P < 0.005) the
ability of rv-cyclin to inhibit expression from the WDSV
promoter. The L257A and V260S mutations resulted in
76% and 87% activity, respectively, which were not
significantly different than control levels. The conserva-
tive V260F mutation enhanced (P < 0.02) the ability of
the rv-cyclin to inhibit transcription (30% luciferase
activity compared with WDSV promoter alone). TheseFig. 3. (A) Individual alignments of overlapping, rv-cyclin 31 a.a. segments
with a prototype acidic activator, VP16 (a.a. 425–451; Cress and
Triezenberg, 1991). Segments span the rv-cyclin activator region, a.a.
228–283, identified in Fig. 2. Similar and identical residues are shaded. /
designates hydrophobic side chains of the VP16 sequence. Asterisks mark
a.a.s L257, D259, and V260 of the rv-cyclin, which were subject to
mutation. (B) Luciferase assay of GAL4-DBD vector, pFA, and GAL4-
DBD GAL4 fusion proteins containing the full-length rv-cyclin, 1–297, or
the wild type (wt) and mutated versions (L257A, D259A, V260A, V260S,
and V260F) of the 240–270 a.a. segment in HeLa cells. (C) Luciferase
assay of GAL4 fusion proteins as in panel B, but performed in the walleye
fibroblast line, W12. (D) Luciferase assay of GAL4 fusions of the entire
carboxy region of VP16 (a.a. 413–490) and double mutant VP16 F442S/
F475A, and subdomains, VP16N (413–452) and VP16C (453–490) and
their corresponding individual mutations of F442S and F475A in HeLa
cells. (E) Assays of the wild type GAL4 DBD-VP16 fusion constructs in
the W12 cell line. Results from the wild type rv-cyclin AD, 240–270, are
shown for comparison.
Fig. 4. Effects of wild type (wt) and mutated full-length rv-cyclin on
transcription. Luciferase expression in W12 cells from the WDSV U3-
luciferase construct, pGL3WDSVU3, co-transfected with control vector
pKH3 or an rv-cyclin expression vector, pKH3OrfA (wild type (wt) or
mutated forms L257A, D259A, V260A, V260S, and V260F).
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tion domain’’ of the rv-cyclin for its ability to inhibit
transcription.
rv-cyclin–cellular protein interactions
Previously, WDSV rv-cyclin was physically associated
with components of transcription complexes, including
RNA Pol II, cdk8, and cyclin C by coIP of transiently
expressed, HA-tagged rv-cyclin in HeLa cells (Rovnak and
Quackenbush, 2002). Additional coIPs confirmed interac-
tions of rv-cyclin with the transcriptional co-activator
complex, Mediator (Fig. 5). Specifically, antibodies to
mediator components, Sur2 (MED23), Med6, CRSP70
(MED26), TRAP95 (MED16), TRAP100 (MED24),
TRAP150 (TRAP3), TRAP220 (MED1), and TRAP230
(MED12, srb8) were able to coIP expressed, HA-tagged rv-
cyclin. Antibodies to transcriptional co-activators, CBP and
p300, and antibodies to TBP and TFIIB, which bind TATA
box DNA, were also able to coIP the rv-cyclin (Fig. 5). An
example of a transcriptional regulatory protein that is not
apparently associated with the rv-cyclin is shown by coIP
with antibody reactive to p53. Overall, only antibodies to
mediator components and to p300 consistently produced
robust coIP of the rv-cyclin.Fig. 5. Western blot analysis of coIPs from 150 Ag HeLa cell lysates. Antibodies
lysates (left lane of each pair) or from lysates of HA-tagged, rv-cyclin-transfected c
immunoprecipitated with preimmune rabbit sera (NRS), and the second two with
precipitated with antibody reactive to the indicated cellular protein. All Westerns w
and TRAP proteins are components of the Mediator co-activator complex. The IP
crossreact.GST pulldown of specific co-activators
To further assess protein–protein contacts, the rv-cyclin
(a.a. 1–297) was expressed as a GST fusion protein and a
small amount of soluble protein purified on glutathione
sepharose. Purified GST-rv-cyclin or purified GST alone
was then rebound to glutathione sepharose and the bound
proteins incubated with HeLa cell nuclear extracts. Protein
complexes pulled down with the glutathione sepharose were
separated by SDS PAGE and Western blots probed
successively with antibodies to p300, Sur2, and TBP. All
three cellular proteins were pulled down with the GST-rv-
cyclin-sepharose only (Fig. 6A).
The carboxy-terminal region (a.a. 219–297) was sim-
ilarly expressed as a GST fusion protein, and the purified
GST fusion or purified GST alone was rebound to
glutathione sepharose and incubated with HeLa cell nuclear
extracts. Bound protein complexes were analyzed by West-
ern blot with antibodies to CBP, p300, Sur2, cdk8, TBP, and
TFIIB (Fig. 6B). CBP, p300, Sur2, TBP, and cdk8 were
identified in the GST-rv-cyclin-sepharose pulldowns and not
with GST-sepharose alone. TFIIB was not visible in the
pulldown fraction. Signals from CBP and p300 were most
robust.
After identification of the rv-cyclin AD (a.a. 240-270), a
GST-AD fusion construct was prepared as were GST-AD
constructs containing the V260S and V260F mutations.
GST fusions of the VP16 AD, and subdomains VP16N and
VP16C, and their corresponding mutations, F442S and
F475A, were also prepared. The GST-rv-cyclin AD pulled
down p300, CBP, Sur2, and cdk8 from HeLa nuclear
extracts (Fig. 6C). The V260F mutation yielded greater
signal for these proteins and also allowed pulldown of TBP.
The V260S mutation reduced or eliminated p300 and CBP
pulldown, and had less affect on Sur2 and cdk8 pulldown,
compared to wild type. This suggests that a principle
component of the AD function is an interaction with CBP
and/or p300.
Comparative assays with GST-VP16N, GST-VP16C,
and GST-VP16 AD demonstrated their different capacities
for the pulldown of co-activators (Fig. 6C): VP16N pulled
down Sur2 and cdk8 well, but not CBP, p300, or TBP;
VP16C pulled down p300, CBP, Sur2, and cdk8 well. The
full VP16 AD pulled down all of the assayed proteins.
The VP16 mutants, F442S and F475A, demonstrated no
or reduced capacity for all interactions. Pulldown resultswere used to precipitate proteins either from control, pKH3-transfected cell
ells (pKH3OrfA vector; right lane of each pair). The first two samples were
rabbit sera reactive to the rv-cyclin protein (rv-cyc). Subsequent pairs were
ere probed with anti-HA MAb (12CA5). Cdk8, cycC, Sur2, Med6, CRSP70,
antibodies used for CBP and p300 are specific for these proteins and do not
Fig. 6. Pulldown of proteins from 75 Ag of HeLa nuclear extracts by GST fusion proteins and glutathione sepharose. (A) Western blot of pulldown by GST-rv-
cyclin (1–297) probed and reprobed with the indicated antibodies specific for p300, Sur2, and TBP. (B) Pulldown by GST fused to the carboxy region of the
rv-cyclin (219–297) and probed successively for p300, CBP, TBP, TFIIB, cdk8, and Sur2. Antibodies for the detection of CBP and p300 detect unique regions
and are not crossreactive. (C) Pulldowns by wild type (wt) GST-rv-cyclin AD (240–270) and mutated forms, V260S and V260F, and by VP16 subdomain
fusions, GST-VP16N and GST-VP16C and GST-VP16 AD and corresponding mutated forms, F442S, F475A, and double mutation, 442S/475A, in the VP16
AD. The input GST fusion proteins were detected with anti-GST (aGST; bottom panel). FGST_ indicates pulldown with purified GST only. Input represents 5%
of total extract used for each pulldown.
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mutants were comparable to those previously published
(Hardy et al., 2002; Ikeda et al., 2002). The capacity of
the rv-cyclin AD to pull down CBP and p300 was most
comparable to that of the VP16C subdomain. The
pulldown of cdk8 by a fragment of the rv-cyclin,
exclusive of its cyclin box domain, and the similar
pulldown of cdk8 by VP16 ADs further support an
association of the rv-cyclin with cdk8 by virtue of its
interaction with Mediator proteins as opposed to its cyclinFig. 7. Pulldown of proteins from 150 Ag of walleye cell nuclear extracts by GST fu
W12 cell nuclear extract by wild type (wt) and mutated (V260S) GST-rv-cyclin A
of p300 and Sur2. (B) Pulldowns from nuclear extracts prepared from regressing w
mutated forms, V260S and V260F and by VP16 subdomain fusions, GST-VP16N
F442S, F475A, and double mutation, 442S/475A, in the VP16 AD. FGST_ indica
used for each pulldown. 2 Ag each of nuclear extracts from W12 cells (WNE)
crossreactivity of antisera to walleye proteins, p300 and Sur2.homology (Holzschu et al., 2003; Rovnak and Quacken-
bush, 2002).
GST pulldown from walleye nuclear extracts
Efforts to pull down and identify proteins from walleye
cell nuclear extracts were limited by the crossreactivity of
specific antibodies across genera. Comparisons between
human genes and genes from the pufferfish (Takifugu
rubripes) indicate the degree of conservation of thesesion proteins and glutathione sepharose. (A) Western blot of pulldown from
D (240–270) probed with antibodies that crossreact with walleye homologs
alleye dermal sarcomas by wild type (wt) GST-rv-cyclin AD (240–270) and
and GST-VP16C and GST-VP16 AD and corresponding mutated forms,
tes pulldown with purified GST only. Input represents 2.5% of total extract
and HeLa cells (HNE) was loaded in the last two lanes and demonstrates
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CBP: 62%, Sur2: 90%, and TBP: 64%. Sequences among
the fish species, pufferfish, and zebrafish (Danio rerio),
share greater identities, and functional domains within the
individual proteins have very high degrees of conservation
from fish to humans. The antibodies to human p300 and
Sur2 were able to detect appropriate size bands in walleye
extracts (Fig. 7). The antibodies used to detect human CBP
and TBP were unable to detect these proteins in walleye
extracts (not shown). Both Sur2 and p300 were detected in
pulldowns from W12 cell nuclear extracts with GST-rv-
cyclin AD, although pulldown of p300 was much less
robust than from HeLa extracts (Fig. 7A). The GST-rv-
cyclin AD with the V260S mutation was negative for the
pulldown of p300 and Sur2 from W12 extracts. Similar
results were obtained with nuclear extracts from regressing
tumors: the V260F and V260S mutations reduced pull-
down of p300, and the V260F mutation enhanced pull-
down of Sur2 (Fig. 7B). This assay included the VP16N,
VP16C, and VP16 AD GST fusions, which could clearly
pull down walleye Sur2, but also pulled down much less
walleye p300 when compared to their pulldown of p300
from HeLa extracts (Fig. 7B). As in luciferase assays,
there was a clear difference between the results from HeLa
cells versus walleye cells, specifically, reduced pulldown
of p300 with both rv-cyclin and VP16 GST-fusion
proteins.Discussion
The results of these studies suggest a common, direct
mechanism for both the activation and inhibition of
transcription by the rv-cyclin. This mechanism is dependent
upon the sequence within the defined activation domain and
requires its physical interaction with co-activators of tran-
scription, Mediator, represented by Sur2 and cdk8, and the
histone acetyl transferase proteins, CBP and p300. In the
context of the larger carboxy region and of the full-length
rv-cyclin or with the specific mutation, V260F, the observed
protein–protein interactions are expanded to include pull-
down of TBP. The data do not identify or confirm a specific
protein targeted for binding by the rv-cyclin, but the results
do indicate a direct protein–protein interaction and function
of the rv-cyclin at the transcription complex.
Comparisons with the activation domains of VP16
served to delineate the rv-cyclin AD and to validate the
protein–protein interactions identified by GST pulldowns
from HeLa cells. Specific CBP or p300 binding motifs
within VP16C have not been identified, nor have specific
sites within CBP and p300 been defined for VP16 contact.
The interactions of VP16 with Mediator have been defined
(Ito et al., 1999; Mittler et al., 2003), but no component of
VP16 is known to interact directly with Sur2 or cdk8. The
use of the VP16 AD constructs also served in the
identification of cell-type or species variations in proteinlevels and protein–protein interactions. Specifically, the
interactions of the GST-VP16, GST-VP16C, and the GST-
rv-cyclin constructs with p300 were greatly reduced in
nuclear extracts from the walleye cell line, W12. In
addition, the levels of p300 in tumor nuclear extracts
appeared to be reduced relative to W12 extracts and in
comparison to Sur2 expression. The inclusion of sufficient
quantities of p300 in complexes bound by either VP16 or
rv-cyclin may profoundly effect the outcome of their
action on transcription.
The functions of AD-containing proteins are also defined
by domains other than the AD. In the case of VP16, the
region 1–412 interacts with Oct-1 POU transcriptional
activators and with HCF-1 (host cell factor) in order to
provide specificity, stability, and cooperativity for activation
of transcription at immediate early genes of HHV1
(Wysocka and Herr, 2003). The rv-cyclin, excluding its
activation and coiled-coil domains, contains a predicted
cyclin box motif (LaPierre et al., 1998). This motif consists
of two repeats of five alpha helical regions. These regions
each define a predicted cyclin box fold, a structure
characterized by low sequence but high structural homology
(Noble et al., 1997). The rv-cyclin box has no apparent
association with cis-acting sequences in the WDSV
promoter or with the DNA-binding proteins known to
contact these sequences. The efforts to identify such
elements were limited to inhibition assays and might not
yet include all possible transcription factors. Also, the
ability of purified rv-cyclin to bind promoter DNA does not
address possible cooperative effects with host cell proteins,
as is the case with VP16 and Oct-1. Although associations
of the rv-cyclin with cis-acting sequences cannot yet be
ruled out entirely, the data to date suggest that the regulation
of gene expression by rv-cyclin is mediated by a general
control of the composition of the transcription complex not
through a specific transcription factor.
The cyclin box motif is common to cyclins and to the
transcriptional regulatory proteins, pRb and TFIIB. The
cyclin box fold is capable of interactions with a variety of
proteins such as the cyclin dependent kinases (cyclins), E2F
(pRb), and TBP and TBP-bound DNA (TFIIB). These
interactions serve to regulate cell cycle and gene expression
(reviewed in Noble et al., 1997). The protein interactions of
the WDSV cyclin box fold are unknown, but the data do not
support direct interaction with known cyclin dependent
kinases per se. The protein interactions of pRb and TFIIB
are quite distinct, so there is no clear indication that the
divergent rv-cyclin should mimic one of these two proteins
or interfere with their function. Of the two, pRb does model
as a regulated repressor of transcription without DNA
binding. Disruption or alteration of the TFIIB-TBP-DNA
ternary complex by the rv-cyclin would certainly lead to
repression of transcription initiation, but it is difficult to
envision such a mechanism for activation. Identification of
specific interactions of the cyclin box folds of the rv-cyclin
awaits further experimentation.
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of WDSV expression appears to be inhibition. The apparent
function of the cyclin box motif, in the context of a GAL4
DBD-rv-cyclin fusion protein, was to block AD function.
This was observed with the segment 95–219 in yeast, with
33–219 in HeLa cells, and with the entire cyclin box motif
in walleye fibroblasts. The latter result suggests a role for
the cyclin box motif in the inhibition of WDSV transcription
in these cells, and the loss of full inhibition with the V260S
mutation indicates the requirement for both the cyclin motif
and a functional AD for inhibition of transcription. The
results in yeast and in HeLa cells may reflect a requirement
for two, intact cyclin box folds for structural stability. An
example of this is the requirement, in the structure of the
pRb pocket domain, for an intact A-box fold for the stable
folding of the B-box (Lee et al., 1998). Intramolecular
interactions between each cyclin box fold of the rv-cyclin
may be required to yield a stable structure with the
appropriate orientation of the AD, but AD inhibition by
an intact cyclin box motif indicates distinctive, species- or
tissue-specific protein–protein interactions that block AD
function in walleye fibroblasts.
The coiled-coil domain (a.a. 228–255) is predicted to
promote rv-cyclin multimers and may function in ways
unrelated to its overlap of AD 240–270. It does not,
however, contain a second rv-cyclin AD (Fig. 2), and loss
of half of the coiled-coil motif (a.a. 228–240) from the
defined AD did not impair its activity, indicating inde-
pendence of the AD from multimerization. Such multimers
may, however, be significant for putative cyclin box
interactions.
A working model that explains the inhibition or
activation of specific promoters can be based on differential
contacts of the rv-cyclin with co-activators or co-repressors.
The isolated rv-cyclin AD shares attributes with powerful
viral transcriptional activators, such as VP16, that are
involved with the selective expression of virus genes.
Without a specific promoter association, the rv-cyclin may
sequester co-activators or co-repressors away from pro-
moters. Alternatively, the association with Mediator com-
ponents suggests function via a complex known to regulate
activated transcription of a subset of cellular genes. Its
association specifically with cdk8 and cyclin C, components
of a mobile Mediator subcomplex, suggests possible control
of Mediator assemblies at the promoter, either by stabiliza-
tion of complexes or by inclusion or exclusion of certain
subcomplexes.
In the context of the tumor model, low levels of spliced
transcripts encoding two WDSV proteins, rv-cyclin (Orf A)
and Orf B, are the only detectable viral transcripts during the
period of tumor growth in infected animals. The lack of full
virus expression is likely to be a critical component of
immune evasion by the virus during tumor growth. The
outcome of this evasion is the successful production of a
mass of cells carrying provirus. At the appropriate time,
during spawning and close fish-to-fish contact, virusexpression shifts radically to virus production, and trans-
mission is maximized by the regression of the tumor mass
and the release of infectious virus to the environment. A
specific role for the rv-cyclin in controlling virus expression
is easy to envision, yet its ability to enhance gene expression
suggests a role in host cell proliferation (in conjunction with
the Orf B protein) as well as a possible contribution to the
shift in virus expression.Materials and methods
Plasmid construction and site-directed mutagenesis
All rv-cyclin sequences, whether full-length or partial
fragments, were derived from the pKH3OrfA construct
(Rovnak et al., 2001). Full-length subclones were pre-
pared directly from the BamHI and EcoRI insertion sites
of the rv-cyclin in the pKH3 vector when possible. When
necessary, and for the cloning of all subfragments, PCR
primers were designed to obtain the desired fragment
sequence and bestow restriction sites and appropriate
reading frame for each vector system. WDSV rv-cyclin-
GAL4 DBD fusions were generated in the pAS2-1 vector
(Clontech), and GAL4 AD fusions were generated in the
pACT2 vector (Clontech). DBD fusions for assays in
metazoan tissue culture cells were generated in the pFA-
CMV vector (Stratagene). Glutathione S-tranferase (GST)
fusion proteins were generated in the pGEX-4T vector
(Pharmacia). The VP16 AD (a.a. 413–490) and mutated
VP16 AD (F442S and F475A) were expressed from the
vectors, pGEX-2T-VP16 and -VP16M, generous gifts
from Andrew P. Rice, Baylor College of Medicine,
Department of Molecular Virology and Microbiology.
The VP16 AD subregions, VP16N (a.a. 413–452; H1)
and VP16C (a.a. 453–490; H2) and their corresponding
mutations, VP16N F442S and VP16C F475A, were
derived by PCR from pGEX2T-VP16 and -VP16M and
cloned in pGEX-4T. Point mutations in the rv-cyclin were
made with the QuikChange site-directed mutagenesis kit
(Stratagene) according to the manufacturer’s instructions
in the context of the pFA-CMV expression construct. The
resulting mutations and the sequences of all constructs
were confirmed by sequence analysis.
Yeast b-glactosidase assays
WDSV rv-cyclin GAL4-DBD and -AD fusion constructs
were introduced into Saccharomyces cerevisiae strain
Y190A by lithium acetate transformation (Schiestl and
Gietz, 1989) and plated on medium lacking histidine,
leucine, or tryptophan in the presence of 25 mM 3-amino
1,2,4-triazole (3-AT). The plates were incubated at 30 -C for
5 days and colonies were screened for h-galactosidase
activity using a colony lift assay (Breeden and Nasmyth,
1985). Quantitative h-galactosidase assays were performed
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Protocols Handbook using o-nitrophenyl h-d-galactopyra-
noside (ONPG) as substrate. Vectors pTD1-1 and pVA3-1
served for expression of positive control DBD and AD
proteins.
Protein expression
GST fusion proteins were expressed in BL21 (DE3)-RIL
cells (Stratagene) by stimulation with 1 mM IPTG for 2 h.
Bacteria were lysed in a French press, and soluble proteins
were purified by affinity chromatography on glutathione
Sepharose (Amersham Pharmacia). Fusion proteins with rv-
cyclin a.a. 219–297 and 240–270 and VP16 ADs were
largely soluble when expressed.
Reporter-gene constructs and luciferase assays
The pGL3-U3 reporter vector contains the WDSV U3
region cloned upstream of the luciferase gene (Hronek et
al., 2004; Rovnak and Quackenbush, 2002). The site-
directed mutations in pGL3-U3 were previously described
(Hronek et al., 2004). HeLa cells were maintained in
Dulbecco’s modified Eagle medium with 10% fetal bovine
serum at 37 -C in 5% CO2. W12 cells, a walleye fibroblast
cell line, were maintained in HEPES buffered minimal
essential media (pH 7.4) with Hank’s salts at 20 -C. Cells
were seeded into 24-well plates in a volume of 1 ml media
supplemented with 10% fetal bovine serum (Gibco), 4 mM
glutamine, 100 units penicillin ml1, and 100 Ag strepto-
mycin ml1 and transfected with 0.2–0.3 Ag of a luciferase
reporter vector and 0.0001 Ag of pRL-TK (Promega) using
FuGENE6 (Roche) according to the manufacturers’ sugges-
tions. Experiments were performed using the dual-luciferase
reporter assay system (Promega). Cell lysates were
harvested 48 h (HeLa) or 72 h (W12) after transfection
with passive lysis buffer and then centrifuged at 20,000  g
for 5 min at 4 -C. Luciferase activities were obtained with a
Turner Designs TD-20/20 or a Beckman Coulter LD400
luminometer. Luciferase activity from the reporter vector
was normalized for transfection efficiency with values from
the co-transfected pRL-TK vector. All transfections were
performed in quadruplicate. Student’s t test and 95%
confidence intervals based on a t distribution were used
for statistical analyses. A P value less than 0.05 was
considered significant.
Co-immunoprecipitation
Co-immunoprecipitation (coIP) was performed as pre-
viously described (Rovnak and Quackenbush, 2002) with
minor modifications. Briefly, HeLa cells were transfected
with control vector, pKH3, or the HA-rv-cyclin vector,
pKH3OrfA. Cells were lysed at 48 h post-transfection with
IP buffer (1% Triton X-100, 0.5% NP-40, 150 mM NaCl,
10 mM Tris–HCl (pH 7.5), 1 mM EDTA pH, 1 mM EGTA,2 Ag/ml leupeptin and aprotinin, 1 Ag/ml pepstatin 0.2 mM
sodium ortho-vanadate, and 0.2 mM PMSF) and pre-cleared
with protein G sepharose (Pharmacia Biotech). 150 Ag
equivalents of cell lysates at 1 Ag/Al IP buffer was incubated
with 0.2–1 Ag of precipitating antibody for 1 h prior to the
addition of 30 Al protein G sepharose suspension (50:50)
and rotated overnight at 4 -C. Protein G pellets were
washed 4 times with IP buffer, suspended in 10 Al loading
buffer, and heated for 10 min at 70 -C. The entire soluble
fraction was separated under denaturing conditions in a 4–
12% polyacrylamide gel, and Western blots were probed
with mouse monoclonal (MAb) reactive to HA (12CA5,
Roche) and detected with goat anti-mouse IgG-peroxidase
conjugate and TMB colorimetric substrate (Kierkegaard and
Perry Labs). 10 Ag of cell lysates was loaded in control
lanes.
GST pulldown
Nuclear extracts from HeLa and walleye cells were
prepared by hypotonic lysis and KCl extraction of nuclei as
described by Mayeda and Krainer (1999). Extracts were
diluted to 2 Ag/Al in D100 buffer (10 mM HEPES pH 8.0,
100 mM KCl, 0.1 mM EDTA, 1 mM DTT, 0.5 mM PMSF,
0.5% NP-40) and pre-adsorbed with 10 Ag purified GST
protein and 50 Al glutathione sepharose CL-4B per mg total
protein extract overnight at 4 -C. 75 Ag (HeLa) or 150 Ag
(walleye) aliquots of pre-adsorbed extracts were rotated
overnight with 2.5 Ag equivalents of glutathione sepharose-
bound GST fusion proteins (10–20 Al of a 10% suspension)
in siliconized microfuge tubes. Relative quantities of bound
input fusion proteins were confirmed by Western analysis
with anti-GST antibody (Pierce). Glutathione sepharose-
bound proteins were pelleted for 8 s in an Eppendorf
microfuge and washed 5 times with 250 Al D100 buffer. The
final pellets were suspended in 8 Al SDS PAGE loading dye,
heated, and the soluble portion separated on 4–12%
gradient gels, and Western blots probed with the indicated
antibodies. Multiple proteins were detected sequentially
after treating blots with strip buffer (30 mM Tris–HCl
(pH6.8), 150 mM NaCl, 1 M h-mercaptoethanol, 0.2%
SDS) for 1 h at 45 -C.
Analysis of protein sequences
Protein sequences used for comparative alignments
were retrieved from the NCBI nr database and included
the HHV1 (HSV1) alpha gene Trans-Inducing Factor
(alpha-TIF, VP16, Vmw65, accession no. NP_044650)
and WDSV rv-cyclin (ORF-A protein, no. AAA99528).
The following accession numbers for human and for T.
rubripes (pufferfish) protein sequences were retrieved from
NCBI nr and Fugu genome (SIN prefix) databases: p300
(nos. NP_001420 and SINFRUP00000072827); CBP
(CREB-Binding Protein, nos. AAC51331 and SIN-
FRUP00000072827); Sur2 (Suppressor of Ras 2, MED23,
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3 (CRSP3), Vitamin D3 Receptor Interacting Protein p130
(DRIP130), or Activator Recruited Cofactor protein p130
(ARC130), nos. NP_004821 and SINFRUP00000080368 +
SINFRUP00000074783 + SINFRUP00000056892 (3 con-
tiguous fragments)); and TBP (TATA Binding Protein, nos.
AAV38463 and AAR24283 (Fugu)).
All protein sequences were aligned with MacVector
multiple sequence alignment software (Accelrys) using the
Clustal W algorithm (Thompson et al., 1994) with the
BLOSUM 30 matrix and an open gap penalty of 10.0 and
extend gap penalty of 0.1.
Antibodies
The antibodies used for Western blots and immunopre-
cipitation included affinity purified rabbit anti-rv-cyclin
(anti-Orf A) (Rovnak et al., 2001), MAb to Sur2 (Pharmin-
gen), MAbs to TBP (ITBP20) and Transcription Factor IIB
(TFIIB8) (Covance), and Santa Cruz MAb to CBP (C-1),
rabbit antibodies reactive to p53 (FL-393) and p300 (N-15),
goat antibodies to cdk8 (C-19), cyclin C (C-19), CRSP 70
(C-19), Med6 (E-20), and to thyroid hormone receptor
proteins (TRAP) 95 (L-15), 100 (C-16), 150 (C-18), 220 (C-
19), and 230 (A-18).Acknowledgments
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